// App-Quantinova.ai

5210 : Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors

Researchers

Presenter

  • Zhen Lu

Principal Investigators

  • Weiqun Mso

  • Janice M. Santiago-O'Farrill

  • Hailing Yang

  • Lan Pang

  • Ahmed A. Ahmed

  • Hariprasad Vankayalapati

  • Robert C. Bast

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • Oxford University, Oxford, United Kingdom

  • Arrien Pharmaceuticals, Sandy, UT

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • High grade serous ovarian cancer

  • Triple-negative breast cancer

  • Ovarian cancer

  • Breast cancer

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • AMP-activated protein kinase

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Exonuclease 1

  • Histone deacetylase 4

  • Hormone receptor

  • BRCA mutation

Drug/Treatment

  • Paclitaxel

  • Olaparib

  • ARN-3236

  • ribose

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved